Arısoy, ÖzdenBeş, CemalÇifci, ÇiğdemSercan, MustafaSoy, Mehmet2021-06-232021-06-2320110924-9338https://hdl.handle.net/20.500.12491/7031https://doi.org/10.1016/S0924-9338(11)73566-0There is a high co-morbidity between chronic inflammatory disorders and depression1. Proinflammatory cytokines like TNFα seems to play a central role in the pathogenesis of these disorders and its neutralization provides a potent treatment for inflammatory disorders2. Trying et al (2006) showed that a TNF-α blocker -etanercept- caused at least a 50% improvement in depression scores in psoriasis patients.3 These observations together with the theoretical background led to the hypothesis that TNF-α blockers may reverse depressive symptoms associated with chronic inflammatory disorders.eninfo:eu-repo/semantics/closedAccessTNFα BlockersConference Object26WOS:000208641302063Q2